BioCatalystWatch
IMRNWorkspace / IMRN / OverviewCompany library
Price
Market cap
Next catalyst—
Cash
Latest company release · Appendix 4G and Corporate Governance Statement ↗

Chart & Events

Candle interval

Core Clinical

Technology Summary

Scientific context

Detailed technology interpretation

Technology advantages

Representative pipeline applications

Disease and market context

Detailed science focus

Background, answer, next evidence

Clinical

Other pipelines

C. difficile toxin B × C. difficile surface-layer proteins

PreINDP1P3FilingApproved

Approved / commercial

ETEC LPS × ETEC CFA-I × ETEC flagellin × LPS O-polysaccharide region × LPS core R region

History / paused

ETEC LPS × ETEC CFA-I × ETEC flagellin × LPS O-polysaccharide region × LPS core R region

PreINDP1P2P3FilingApproved

ETEC LPS × ETEC CFA-I × ETEC flagellin × LPS O-polysaccharide region × LPS core R region

ETEC LPS × ETEC CFA-I × ETEC flagellin × LPS O-polysaccharide region × LPS core R region

PreINDP1P2P3FilingApproved

Financial position

Cash and cash equivalents

Source and basis

Short-term investments

Net operating cash flow

Source and basis

Company funding outlook

Upcoming milestones

Financial history

Amounts and sources
PeriodCashCurrent investmentsOperatingInvestingFinancing

Source

PeriodCashCurrent investmentsOperatingInvestingFinancing

Source

PeriodCashCurrent investmentsOperatingInvestingFinancing

Source

PeriodCashCurrent investmentsOperatingInvestingFinancing

Source

Annual trends

Reported item

Reported shares and borrowings

Source and basis

Ownership and institutions

Status

Market Reaction / Supply Context

Market Structure

Latest company release · Appendix 4G and Corporate Governance Statement ↗

IMRN PR & News

PR & News

IMRN SEC archive